← Browse by Condition

Medical Condition

immunotherapy

Total Trials

25

Recruiting Now

25

Trial Phases

Phase 2, Phase 3, Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for immunotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — immunotherapy Clinical Trials

How many clinical trials are currently recruiting for immunotherapy?

ClinicalMetric currently tracks 25 actively recruiting clinical trials for immunotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 25. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for immunotherapy?

immunotherapy research spans Phase 1 (2 trials), Phase 2 (8 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a immunotherapy clinical trial?

Eligibility criteria for immunotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

2

Phase 2

8

Phase 3

4

Top Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1 trial

Centre Hospitalier Universitaire, Amiens 1 trial

West China Hospital 1 trial

Mahidol University 1 trial

Qilu Hospital of Shandong University 1 trial

Recruiting Clinical Trials

NCT06826079 Phase 2, Phase 3

Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer

Union Hospital, Tongji Medical...

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Centre Hospitalier Universitai...

NCT07020247 Phase 3

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

West China Hospital

Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy

Mahidol University

Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma

Qilu Hospital of Shandong Univ...

Toripalimab Combined With Definitive CCRT for LACC Patients

Ruijin Hospital

NCT06985485 Phase 2

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

The First Affiliated Hospital ...

NCT05825443 Phase 2

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

Nanfang Hospital, Southern Med...

NCT06889649 Phase 2

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

Peking University First Hospit...

NCT06702826 Phase 2

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

NCT07085234 Phase 2

Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC

The First Affiliated Hospital ...

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment

Shanghai Chest Hospital

NCT06307249 Phase 1

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Lebanese University

Immunotherapy for Hepatocellular Carcinoma

The First Affiliated Hospital ...

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Oxford Biodynamics Inc.

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

Medical University of Graz

NCT06716619 Phase 1

A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors

Guangzhou FineImmune Biotechno...

NCT06676449 Phase 3

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Fudan University

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Hubei Cancer Hospital

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

United States, Greec...

Oncology Center of Biochemical...

NCT04278222 Phase 2

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

Shanghai Changzheng Hospital

NCT06165900 Phase 2

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Shengjing Hospital

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Sun Yat-sen University

NCT06500234 Phase 3

Nutrition Impact on Immunotherapy of Cancer

Qingdao Central Hospital

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

Beijing Chao Yang Hospital

Related Conditions

radiotherapy (4) cancer (3) gastric cancer (2) chemotherapy (2) targeted therapy (2) non small cell lung cancer (2) colorectal cancer (2) breast cancer (2) hepatocellular carcinoma (2) gastric junction adenocarcinoma (1) neoadjuvant therapies (1) immune checkpoint inhibitors (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology